DEUTSCHE BANK AG\ - TG THERAPEUTICS INC ownership

TG THERAPEUTICS INC's ticker is TGTX and the CUSIP is 88322Q108. A total of 123 filers reported holding TG THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.23 and the average weighting 0.1%.

Quarter-by-quarter ownership
DEUTSCHE BANK AG\ ownership history of TG THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$781,969
-67.2%
93,537
-2.5%
0.00%0.0%
Q2 2023$2,383,348
+26.4%
95,948
-23.5%
0.00%0.0%
Q1 2023$1,885,475
+59.0%
125,364
+25.1%
0.00%0.0%
Q4 2022$1,185,555
+114.0%
100,216
+7.0%
0.00%
Q3 2022$554,000
+35.5%
93,628
-2.9%
0.00%
Q2 2022$409,000
-46.9%
96,412
+19.1%
0.00%
Q1 2022$770,000
-75.7%
80,957
-51.5%
0.00%
-100.0%
Q4 2021$3,175,000
-43.8%
167,091
-1.5%
0.00%
-66.7%
Q3 2021$5,647,000
-11.9%
169,662
+2.7%
0.00%0.0%
Q2 2021$6,410,000
-18.9%
165,228
+0.8%
0.00%
-25.0%
Q1 2021$7,903,000
+32.0%
163,966
+42.5%
0.00%0.0%
Q4 2020$5,985,000
+182.8%
115,070
+45.5%
0.00%
+300.0%
Q3 2020$2,116,000
+65.1%
79,070
+20.1%
0.00%0.0%
Q2 2020$1,282,000
+39.5%
65,841
-29.4%
0.00%0.0%
Q1 2020$919,000
-16.4%
93,302
-5.9%
0.00%0.0%
Q4 2019$1,099,000
+60.0%
99,115
-19.2%
0.00%
Q3 2019$687,000
-35.7%
122,602
-0.8%
0.00%
-100.0%
Q2 2019$1,068,000
+103.4%
123,561
+88.8%
0.00%
Q1 2019$525,000
-84.5%
65,440
-92.1%
0.00%
-100.0%
Q4 2018$3,378,000
-47.9%
824,164
-28.8%
0.00%0.0%
Q3 2018$6,480,000
+132.8%
1,157,397
+446.7%
0.00%
+100.0%
Q2 2018$2,783,000
+5.6%
211,705
+13.9%
0.00%0.0%
Q1 2018$2,636,000
+173.2%
185,798
+57.5%
0.00%0.0%
Q4 2017$965,000
+26.8%
117,990
+83.5%
0.00%0.0%
Q3 2017$761,000
-10.5%
64,306
-24.1%
0.00%0.0%
Q2 2017$850,000
+474.3%
84,706
+562.1%
0.00%
Q1 2017$148,000
+15.6%
12,794
-53.9%
0.00%
Q4 2016$128,000
-35.0%
27,752
+8.1%
0.00%
Q3 2016$197,000
-50.4%
25,680
-61.0%
0.00%
Q2 2016$397,000
-13.7%
65,776
+21.6%
0.00%
Q1 2016$460,000
-32.6%
54,088
-5.4%
0.00%
Q4 2015$682,000
-55.4%
57,190
-62.3%
0.00%
-100.0%
Q3 2015$1,530,000
+10.6%
151,844
+82.0%
0.00%0.0%
Q2 2015$1,383,000
-28.2%
83,443
-33.0%
0.00%0.0%
Q1 2015$1,926,000
+66.8%
124,517
+70.6%
0.00%0.0%
Q4 2014$1,155,000
+98.5%
72,989
+33.5%
0.00%
Q3 2014$582,000
+13.9%
54,669
+0.2%
0.00%
Q2 2014$511,000
+153.0%
54,560
+85.3%
0.00%
Q1 2014$202,000
-1.9%
29,440
-44.5%
0.00%
Q4 2013$206,000
+123.9%
53,010
+186.2%
0.00%
Q3 2013$92,00018,5230.00%
Other shareholders
TG THERAPEUTICS INC shareholders Q2 2019
NameSharesValueWeighting ↓
RA Capital Management 6,880,323$38,633,0002.30%
Eversept Partners, LP 773,501$4,343,2081.35%
Opaleye Management Inc. 612,500$3,439,0001.24%
BRIDGER MANAGEMENT, LLC 2,334,196$13,107,0001.08%
Sofinnova Investments, Inc. 1,733,628$9,734,0000.88%
PURA VIDA INVESTMENTS, LLC 354,719$1,992,0000.34%
683 Capital Management, LLC 400,000$2,246,0000.25%
NEXPOINT ASSET MANAGEMENT, L.P. 649,460$3,646,0000.23%
Artal Group S.A. 900,000$5,054,0000.20%
Frontier Wealth Management LLC 226,750$1,273,0000.19%
View complete list of TG THERAPEUTICS INC shareholders